Choosing blastocysts for transfer based on size could give prospective parents a much better chance of success in welcoming a new member to the family, a study published in the Nature portfolio journal Scientific Reports demonstrates.
For the one in eight couples struggling to conceive, the improvements in infertility treatments achieved by employment of artificial intelligence (AI) in diagnostics, personalized therapies and embryo selection may soon mean the difference between childlessness and the family of their dreams.
Two Israeli companies aiming to improve in vitro fertilization (IVF) success rates received good news recently, with Aivf Ltd. hauling in $25 million in a series A round for Ema, its IVF software platform, and Fairtility Ltd. gaining CE mark for its CHLOE EQ embryo quality decision-support tool.
Proving that reproduction remains a fecund market for investment, Israeli startup Fairtility Ltd. closed a $15 million series A funding round. Led by Boston-based Gurnet Point Capital with support from Nacre Capital and others, the round boosted Fairtility’s funding to date up to $18.5 million.
Fairtility Ltd.’s artificial intelligence (AI)-trained embryo classification system offers patients struggling with infertility and their physicians a better way to maximize the likelihood of implantation following in vitro fertilization (IVF) without the risk of a multiple pregnancy, a study in the Nature portfolio journal Scientific Reports found.
